CanSino Biologics (simplified Chinese: 康希诺生物; traditional Chinese: 康希諾生物; pinyin: Kāngxīnuò Shēngwù), often abbreviated as CanSinoBIO, is a Chinese vaccine company. [1]

Jun 10, 2022 · Clinical trial data showed that the Ad5-nCoV vaccine had an efficacy of 58% against symptomatic disease and 92% against severe COVID-19. What is the recommended dosage? SAGE recommends the use of Ad5-nCoV vaccine as a single dose (0.5 ml) given intramuscularly into the deltoid muscle. Is a booster recommended for the vaccine?

康希诺生物股份公司成立于中国，以在世界范围内提供预防和治疗感染类疾病的解决方案为己任，专注于创新、优质、可及的人用疫苗的研发、生产和商业化，是行业领先的高科技生物制品企业。 【E药经理人】重估康希诺：逆势大增背后，信心从哪来？ 作为创新疫苗研发领军企业，我们重视社会价值的实现，不断完善ESG治理机制，以维护全球公共卫生安全为己任，积极履行社会及国际责任，矢志不渝地研发和提供高质量的疫苗产品，为全球公共卫生事业做出贡献。

CanSinoBIO is an industry-leading biopharmaceutical company, dedicated to providing global solutions for the prevention and treatment of infectious diseases, through research & development, manufacturing and commercialization of vaccine products for human use.

AD5-nCOV, trade-named Convidecia, is a single-dose [2] viral vector vaccine for COVID-19 that is also used as an inhaled booster. It was developed by CanSino Biologics, with Phase III trials conducted in Argentina, [3] Chile, [4] Mexico, [5] Pakistan, [6] Russia, [7] and Saudi Arabia [8] with 40,000 participants.

Sep 6, 2022 · The vaccine maker, CanSino Biologics, said in a statement Sunday that China’s medicines regulator had approved the inhaled dose for emergency use as a booster vaccine. The product, known as...

May 19, 2022 · The U.N. health agency said the single-dose CanSino vaccine was found to be about 92% effective against severe COVID-19 and 64% effective in preventing people from getting symptoms of the disease. WHO’s expert vaccine group recommended the vaccine for everyone age 18 and over.

CanSinoBIO has developed five key platform technologies, including Adenovirus-based viral vector technology, Synthetic biotechnology, Protein structure design and VLP assembly, mRNA and LNP technology as well as Formulation and drug delivery technology.

May 19, 2022 · Conoce cuáles son los efectos secundarios de la vacuna CanSino, su origen, quién no debe recibirla y su uso en México. Recientemente fue aprobada por la OMS.

CanSino (CanSinoBIO, Tianjin, China) is a recombinant viral vector vaccine developed by China. It uses adenovirus as a vector to transfer the genes that code for COVID-19 proteins to human cells, resulting in the production of deactivating antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).